The 81st Annual Meeting of the Japanese Society of Hematology

Session information

Oral Session

Oral Session 2-7C ATL: Treatment

Sat. Oct 12, 2019 2:50 PM - 3:50 PM No.7 (Tokyo International Forum, 5F Hall D5)

Chair: Masao Matsuoka (Dept Hematol, Rheumatol, and Inf Dis, Kumamoto University)

Ilseung Choi1, Shigeru Kusumoto2, Nobuaki Nakano3, Asahi Ito2, Kentaro Yonekura3, Yoshitaka Imaizumi4, Makoto Yoshimitsu5, Kisato Nosaka6, Eiichi Otsuka7, Michihiro Hidaka8, Tatsuro Jo9, Hidenori Sasaki10, Yukiyoshi Moriuchi11, Masao Ogata12, Yoko Suehiro1, Ryuzo Ueda13, Atae Utsunomiya3, Takashi Ishida2 (1.Department of Hematology NHO Kyushu Cancer Center Fukuoka Japan, 2.Department of Hematology and Oncology, Nagoya City University, 3.Department of Hematology, Imamura General Hospital, 4.Department of Hematology, Atomic Disease Institute, Nagasaki University, 5.Department of Hematology and Immunology, Kagoshima University, 6.Department of Hematology, Kumamoto University, 7.Department of Hematology, Oita Prefectural Hospital, 8.Department of Hematology, NHO Kumamoto Medical Center, 9.Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, 10.Division of Medical Oncology, Hematology, and Infectious Diseases, Fukuoka University, 11.Department of Hematology, Sasebo City General Hospital, 12.Department of Hematology, Oita University, 13.Department of Tumor Immunology, Aichi Medical University School of Medicine)

Ayumu Ito1, Nobuaki Nakano2, Takashi Tanaka1, Shigeo Fuji3, Junya Makiyama4, Yoshitaka Inoue5, Ilseung Choi6, Hirohisa Nakamae7, Koji Nagafuji8, Ken Takase9, Shinichiro Machida10, Tsutomu Takahashi11, Yasushi Sawayama12, Tomohiko Kamimura13, Koji Kato14, Toshiro Kawakita15, Masao Ogata16, Rika Sakai17, Souichi Shiratori18, Yoshihiro Inamoto1, Kaoru Uchimaru19, Atae Utsunomiya2, Takahiro Fukuda1 (1.Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan, 2.Hematology, Imamura General Hospital, Kagoshima, Japan, 3.Hematology, Osaka International Cancer Institute, Osaka, Japan, 4.Hematology/Oncology, IMSUT Hospital, Tokyo, Japan, 5.Hematology, Kumamoto University Hospital, Kumamoto, Japan, 6.Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, 7.Hematology, Osaka City University Hospital, Osaka, Japan, 8.Hematology and Oncology, Kurume University Hospital, Fukuoka, Japan, 9.Hematology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan, 10.Hematology and Oncology, Tokai University Hospital, Kanagawa, Japan, 11.Oncology/Hematology, Shimane University Hospital, Shimane, Japan, 12.Hematology, Nagasaki University Hospital, Nagasaki, Japan, 13.Hematology, Harasanshin Hospital, Fukuoka, Japan, 14.Hematology, Oncology and Cardiovascular medicine, Kyushu University Hospital, Fukuoka, Japan, 15.Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan, 16.Hematology, Oita University Hospital, Oita, Japan, 17.Hematology and Medical Oncology, Kanagawa Cancer Center, Kanagawa, Japan, 18.Hematology, Hokkaido University Hospital, Sapporo, Japan, 19.Graduate School of Frontier Sciences, The University of Tokyo, Japan)

Nobuaki Nakano1, Ayumu Kubota1, Tomohisa Tabuchi1, Jun Odawara1, Kentaro Yonekura2, Masahito Tokunaga1, Takayoshi Miyazono1, Atae Utsunomiya1, Yoshikiyo Ito1 (1.Department of Hematology, Imamura General Hospital, Kagoshima, Japan, 2.Department of Dermatology, Imamura General Hospital. Kagoshima, Japan)